

B²
concluded
(250 ml); after triethylamine (3 ml) was added, the solution was filtered through a 0.45 μ m filter.

After the filtrate was concentrated, hexane was added, and the filtrate was again evaporated to dryness to yield

In the Claims

Please cancel claims 1, 2 and 5 without prejudice to the filing of future continuing applications.

Please substitute the following claims 3, 4, 6 and 7 for the claims 3, 4, 6 and 7 now pending in the above-identified application.

Please add new claims 8-11.

1. ~~3~~. (Once Amended) A crystal of (R)-2-(((3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl)methyl)sulfinyl)-1H-benzimidazole wherein the X-ray powder diffraction analysis pattern has characteristic peaks at interplanar spacings (d) of 11.68, 6.77, 5.84, 5.73, 4.43, 4.09, 3.94, 3.89, 3.69, 3.41 and 3.11 Angstrom.

3 ~~4~~. (Once Amended) A pharmaceutical composition which comprises the crystal according to Claim ~~3~~¹ and a pharmaceutically acceptable excipient, carrier or diluent.

B³ ~~5~~ 6. (Once Amended) A method for treating or preventing digestive ulcer in a mammal in need thereof which comprises administering to said mammal an effective amount of the crystal according to Claim ~~3~~¹ with a pharmaceutically acceptable excipient, carrier or diluent.

~~5~~ ~~7~~ (Twice Amended) A method for manufacturing a pharmaceutical composition for treating or preventing digestive ulcer comprising formulating the composition with the crystal of Claim ~~3~~¹.

2. ~~8~~. (NEW) A crystal of (R)-2-(((3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl)methyl)sulfinyl)-1H-benzimidazole 1.5 hydrate wherein the X-ray powder diffraction analysis pattern has characteristic peaks at interplanar spacings (d) of 13.22, 9.60, 8.87, 8.05, 6.61, 5.92, 5.65, 5.02, 4.49, 3.50 and 3.00 Angstrom.

4 ~~9~~ (NEW) A pharmaceutical composition which comprises the crystal according to Claim ~~8~~² and a pharmaceutically acceptable excipient, carrier or diluent.

8. 10. (NEW) A method for treating or preventing digestive ulcer in a mammal in need thereof
which comprises administering to said mammal an effective amount of the crystal according
to Claim ² 8 with a pharmaceutically acceptable excipient, carrier or diluent.

B³
conced
7. 11. (NEW) A method for manufacturing a pharmaceutical composition for treating or
preventing digestive ulcer comprising formulating the composition with the crystal of Claim
²
8.

35

5